Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Beats Expectations By $4.13 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its earnings results on Thursday. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13, FiscalAI reports. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the company earned $12.81 earnings per share.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Strong second-quarter performance: Total revenue rose 17% year over year to $4.3 billion, while non-GAAP EPS increased 11% to $14.29. Dupixent, EYLEA HD, and Libtayo each reached record quarterly sales.
• Dupixent momentum remains robust, with global sales of $6 billion, up 38% at constant exchange rates, supported by growth across existing indications and newer launches. Growth is expected to remain strong, though it will moderate in the second half due to tougher comparisons.
• EYLEA HD is rapidly converting the U.S. franchise: sales increased 52% year over year to $596 million and exceeded legacy EYLEA sales for the first time. Regeneron is pursuing approval of a pre-filled syringe, which management believes could further improve adoption.
• Several pipeline catalysts are approaching, including potential FDA decisions for cemdisiran in generalized myasthenia gravis in November and garetosmab in FOP in August, along with data readouts for the PNH complement program and geographic atrophy program later this year.
• Legacy EYLEA remains under pressure: U.S. sales fell 45% year over year to $412 million as patients converted to EYLEA HD and competition increased. Management expects further low-to-mid-teens sequential demand declines in the second half, partly because of multiple aflibercept biosimilar launches.

Regeneron Pharmaceuticals Price Performance

REGN traded up $24.29 during trading hours on Friday, hitting $762.63. The company’s stock had a trading volume of 1,158,212 shares, compared to its average volume of 727,605. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a current ratio of 4.29, a quick ratio of 2.96 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $643.13 and its 200-day moving average price is $711.70. The stock has a market cap of $80.63 billion, a price-to-earnings ratio of 18.85, a P/E/G ratio of 29.50 and a beta of 0.24.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results
• Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates
• Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst.
• Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action

Analyst Upgrades and Downgrades

REGN has been the topic of several analyst reports. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday. Canaccord Genuity Group decreased their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Leerink Partners reissued a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $794.83.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Compound Planning Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 69.3% during the 4th quarter. Compound Planning Inc. now owns 1,676 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 686 shares during the period. Birchwood Financial Partners Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $32,000. Corient Private Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 32.5% in the fourth quarter. Corient Private Wealth LLC now owns 23,019 shares of the biopharmaceutical company’s stock worth $17,768,000 after purchasing an additional 5,647 shares during the last quarter. Alpine Woods Capital Investors LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $247,000. Finally, Ameriflex Group Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $112,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.